These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 36308526)
1. Adjuvant radiotherapy in patients with node-positive prostate cancer after radical prostatectomy. Chen H; Qu M; Shi H; Dong Z; Wang Y; Gao X J Cancer Res Clin Oncol; 2023 Jul; 149(8):4925-4932. PubMed ID: 36308526 [TBL] [Abstract][Full Text] [Related]
2. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy. Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728 [TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up comparing salvage radiation therapy and androgen-deprivation therapy for biochemical recurrence after radical prostatectomy. Matsumoto K; Niwa N; Hagiwara M; Kosaka T; Takeda T; Yasumizu Y; Tanaka N; Morita S; Mizuno R; Shinojima T; Hara S; Asanuma H; Oya M Int J Clin Oncol; 2021 Apr; 26(4):744-752. PubMed ID: 33387085 [TBL] [Abstract][Full Text] [Related]
5. Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis. Guo L; Zhu Z; Zhang X Medicine (Baltimore); 2020 Mar; 99(10):e19153. PubMed ID: 32150055 [TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125 [TBL] [Abstract][Full Text] [Related]
7. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D; Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497 [TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus androgen deprivation therapy for prostate-specific antigen persistence in lymph node-positive prostate cancer. Shiota M; Takamatsu D; Kimura T; Tashiro K; Matsui Y; Tomida R; Saito R; Tsutsumi M; Yokomizo A; Yamamoto Y; Edamura K; Miyake M; Morizane S; Yoshino T; Matsukawa A; Narita S; Matsumoto R; Kasahara T; Hashimoto K; Matsumoto H; Kato M; Akamatsu S; Joraku A; Kato M; Yamaguchi T; Saito T; Kaneko T; Takahashi A; Kato T; Sakamoto S; Enokida H; Kanno H; Terada N; Suekane S; Nishiyama N; Eto M; Kitamura H; Cancer Sci; 2022 Jul; 113(7):2386-2396. PubMed ID: 35485635 [TBL] [Abstract][Full Text] [Related]
9. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer. Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018 [TBL] [Abstract][Full Text] [Related]
10. Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis. Si S; Zheng B; Wang Z; Niu Z Prostate; 2021 Aug; 81(11):736-744. PubMed ID: 34056739 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184 [TBL] [Abstract][Full Text] [Related]
12. Risk factors for clinical metastasis in men undergoing radical prostatectomy and immediate adjuvant androgen deprivation therapy. Taguchi S; Fukuhara H; Kakutani S; Takeshima Y; Miyazaki H; Suzuki M; Fujimura T; Nakagawa T; Igawa Y; Kume H; Homma Y Asian Pac J Cancer Prev; 2014; 15(24):10729-33. PubMed ID: 25605166 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. Gupta M; Patel HD; Schwen ZR; Tran PT; Partin AW BJU Int; 2019 Feb; 123(2):252-260. PubMed ID: 29626845 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy. Kim D; Kim DY; Kim JS; Hong SK; Byun SS; Lee SE PLoS One; 2021; 16(9):e0256778. PubMed ID: 34506516 [TBL] [Abstract][Full Text] [Related]
15. Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study. Castelli T; Russo GI; Favilla V; Urzi D; Spitaleri F; Reale G; Giardina R; Saita A; Madonia M; Cimino S; Morgia G Int Braz J Urol; 2014; 40(3):322-9. PubMed ID: 25010298 [TBL] [Abstract][Full Text] [Related]
16. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466 [TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. Ventimiglia E; Seisen T; Abdollah F; Briganti A; Fonteyne V; James N; Roach M; Thalmann GN; Touijer K; Chen RC; Cheng L Eur Urol Oncol; 2019 May; 2(3):294-301. PubMed ID: 31200844 [TBL] [Abstract][Full Text] [Related]
18. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176 [TBL] [Abstract][Full Text] [Related]
19. Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT. Hutten R; Tward JD Clin Genitourin Cancer; 2022 Jun; 20(3):e263-e269. PubMed ID: 35304077 [TBL] [Abstract][Full Text] [Related]
20. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]